🌎 Ship to: United States
Toggle Nav
Carrello
Cerca
Spedizione in giornata per tutti gli articoli disponibili in magazzino.
Ricerca avanzata
Ordine rapido SDS / CoA Structure Massivo e personalizzato
Menu
Account
Impostazioni
྾
224,000+ prodotti di ricerca · Triple ISO certified · COA & SDS Disponibile per ogni prodotto · Spedizione lo stesso giorno su articoli in magazzino

OSTN (81-102), Agonist of chemerin receptor 2, CAS No.rp174705, Agonist of chemerin receptor 2

CAS: rp174705 Cat. No.: rp174705
COA
OSTN (81-102), Agonist of chemerin receptor 2, CAS No.rp174705, Agonist of chemerin receptor 2
Disponibile su ordine
GRADE & PURITY Moligand™ ? Moligand™ — Aladdin's line of ligands and bioactive small molecules. Use for receptor, pathway, and binding studies needing defined small-molecule tools.
★
Size
Germania (EU)
USA*
Price
Qty
500μg
rp174705-500μg
Su ordinazione · 8–12 settimane
2.082,49€
1mg
rp174705-1mg
Su ordinazione · 8–12 settimane
3.470,87€
Enter a quantity for the sizes you want to add.
Bulk / Custom
♡ Lista dei desideri ⇅ Aggiungi al confronto ⎙ Print page
SDS
Safety data
COA
Certificate
DS
Datasheet
SP
Spec sheet
Specifications Stoccaggio e spedizione Documentazione Advanced Data Obiettivi associati (umani) Certificati (CoA, COO, BSE/TSE e tabella di analisi) Informazioni genetiche Calcolatori di soluzioni Recensioni Application Protocols Biological Roles Buffer Applications Green Alternatives Pharmaceutical Uses Physical Properties Quality and Grades Reaction and Applications Reaction Conditions Safety and Handling Solvent Selection Storage and Reconstitution Structure and Identity Synthetic Utility Target Specificity
🧪
Why this grade

Moligand™ Moligand™ for sensitive chromatographic and analytical workflows requiring minimal baseline interference.

🌡

Storage & shipping

Room temperature Ships Check lot-specific COA for exact specifications.

📋

Quality documents

SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.

📚

Literature proof

Cited in 0 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.

Specifications

Product Name
OSTN (81-102), Agonist of chemerin receptor 2, CAS No.rp174705
Grado
Moligand™
Specifiche e purezza
Moligand™
Tipo di azione
AGONIST
Meccanismo d'azione
Agonist of chemerin receptor 2
CAS
rp174705
Tipo di molecola
Peptidi
Product Line
Prodotti biologici
Stoccaggio e spedizione
Condizioni di conservazione di stoccaggio
Room temperature

Documentazione

📋 Safety Data Sheet (SDS)

Comprehensive hazard, handling, storage, and regulatory compliance document.

Download SDS →

✅ Certificate of Analysis (COA)

Lot-specific quality data. Enter your lot number to retrieve the exact COA.

Look up COA →

📊 Datasheet

Quick-reference summary of product specifications and applications.

View datasheet →

🔬 Specification Sheet

Full quality attributes and acceptance criteria for this grade.

View spec sheet →

Advanced Data

Obiettivi associati (umani)
GPR1 Tchem G-protein coupled receptor 1 (0 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
Certificati (CoA, COO, BSE/TSE e tabella di analisi)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:
Informazioni genetiche
Reference
  • 1. Kinetics and inhibition of recombinant human cystathionine gamma-lyase. Toward the rational control of transsulfuration., The Journal of biological chemistry, Steegborn, C C and 7 more authors.
  • 2. Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences., Proceedings of the National Academy of Sciences of the United States of America, Strausberg, Robert L RL and 83 more authors.
  • 3. Genomic basis of cystathioninuria (MIM 219500) revealed by multiple mutations in cystathionine gamma-lyase (CTH)., Human genetics, Wang, Jian J and Hegele, Robert A RA.
  • 4. Cloning and nucleotide sequence of human liver cDNA encoding for cystathionine gamma-lyase., Biochemical and biophysical research communications, Lu, Y Y, O'Dowd, B F BF, Orrego, H H and Israel, Y Y.
  • 5. Single nucleotide polymorphism in CTH associated with variation in plasma homocysteine concentration., Clinical genetics, Wang, J J, Huff, A M AM, Spence, J D JD and Hegele, R A RA.
  • 6. Cystathionine gamma-lyase overexpression inhibits cell proliferation via a H2S-dependent modulation of ERK1/2 phosphorylation and p21Cip/WAK-1., The Journal of biological chemistry, Yang, Guangdong G, Cao, Kun K, Wu, Lingyun L and Wang, Rui R.
  • 7. The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)., Genome research, Gerhard, Daniela S DS and 115 more authors.
  • 8. Towards a proteome-scale map of the human protein-protein interaction network., Nature, Rual, Jean-François JF and 37 more authors.
  • 9. The DNA sequence and biological annotation of human chromosome 1., Nature, Gregory, S G SG and 178 more authors.
  • 10. Polymorphisms in one-carbon metabolism and trans-sulfuration pathway genes and susceptibility to bladder cancer., International journal of cancer, Moore, Lee E LE and 14 more authors. more
Calcolatori di soluzioni
Recensioni

Recensioni dei clienti

Application Protocols

  • Item-specific

    • Tested applications, recommended dilutions, and positive controls are not provided for this product. Not specified for this item; refer to CoA/Spec Sheet and SDS.

  • Guidance

    • Follow internal lab SOPs for peptide dissolution, aliquoting, and assay setup. Validate concentration by UV (214/280 nm as appropriate) or amino acid analysis when accuracy is critical.
Biological Roles

  • Item-specific

    • No biological role or target information is specified for this item in the Product Data.

  • Literature/context (osteocrin, general)

    • Osteocrin (OSTN) is a secreted, extracellular peptide/protein implicated in musculoskeletal and cardiovascular biology in vertebrates. C‑terminal fragments of secreted proteins can modulate receptor interactions, bioavailability, or clearance pathways.
    • Reported themes for OSTN in the literature include modulation of natriuretic peptide signaling via interactions influencing clearance receptor pathways and potential roles in tissue growth and adaptation. Specific binding partners, affinities, and effects depend on the exact sequence and experimental system.
    • Peptide fragments such as residues 81–102 are often used as tools to delineate structure–function relationships, identify minimal binding motifs, and benchmark potency relative to full‑length proteins or alternative fragments.

  • Research use only

    • Any discussion above reflects general biochemical knowledge and is not specific to this catalog item. Do not use for diagnostic or therapeutic purposes. Verify sequence, modifications, and analytical data on the CoA to interpret biological findings appropriately.
Buffer Applications

  • Item-specific

    • No buffer recipes or pH ranges are specified for this item; refer to CoA/Spec Sheet.

  • Literature/context (peptide stocks and assay buffers)

    • Stock preparation: Common practice is to prepare 1–10 mM peptide stocks in water, buffer, or DMSO depending on solubility, then dilute into assay buffer (e.g., PBS, HEPES, or Tris) immediately before use.
    • pH considerations: Choose buffer pH to increase ionization of poorly soluble peptides (slightly acidic for basic peptides; mildly basic for acidic peptides). Typical working pH: 6.5–8.0 for most biochemical assays.
    • Ionic strength: 100–150 mM NaCl helps maintain peptide solubility and reduces nonspecific adsorption in biophysical assays.
    • Additives: 0.01–0.05% polysorbate 20/80 or 0.1% BSA can mitigate surface adsorption where assay‑compatible. Include only if validated for your readout.
    • Filtration: Use low protein‑binding filters (PVDF, PES) when sterile filtration is required.

Note: These are general guidelines for peptide handling; this item’s exact sequence, charge, and solubility profile are not specified.

Green Alternatives

  • Context

    • Peptide handling centers on solvent and buffer selection rather than synthetic replacement.

  • Greener choices (general guidance)

    • Prefer aqueous buffers (water, PBS, HEPES) over high‑fraction organic solvents whenever solubility permits.
    • If a pre‑solvent is required, minimize DMSO content in final working solutions (<1–2% v/v) and opt for water‑miscible, low‑toxicity co‑solvents when feasible (e.g., glycerol in enzymatic assays, noting viscosity trade‑offs).
    • Avoid halogenated solvents (e.g., HFIP, TFA in bulk) except where analytically necessary; consider acetic acid or formic acid for pH adjustment in preparative contexts.

  • Comparison (general)

    • DMSO vs water-based buffers:
      • Environmental impact: Water-based buffers have lower environmental and safety burdens than DMSO.
      • Performance: DMSO can enhance solubility of hydrophobic peptides; buffers are preferred for biological compatibility.
    • TFA vs acetic acid (for dissolution/acyl counterions):
      • TFA offers strong acidity and volatility but presents disposal and safety concerns; acetic acid is milder and generally greener but may be less effective for very basic sequences.

  • Procurement/format

    • Request aqueous, ready‑to‑use formulations or salt forms that aid solubility (acetate) when available to reduce solvent use. Confirm availability on the CoA; not specified for this item.
Pharmaceutical Uses

  • Item-specific

    • No pharmacopeial status, excipient role, or formulation guidance is specified for this item; refer to CoA/Spec Sheet.

  • Literature/context (research formulation)

    • Defined peptide fragments are frequently used as model compounds in formulation screening (solubility enhancers, stabilizing excipients, lyophilization cycles) and delivery research (permeation enhancers, depot systems) strictly within preclinical research.
    • Typical excipients evaluated include isotonic buffers, sugars (trehalose, sucrose), amino acids (arginine), polymers (PEG, poloxamers), and surfactants (polysorbates) to mitigate aggregation and adsorption.

  • Compliance note

    • This product is supplied for research use only and is not intended for human or veterinary use. No therapeutic or clinical claims are made.
Physical Properties

  • Item-specific (from Product Data)

    • Appearance: Not specified for this item; refer to CoA/Spec Sheet.
    • Molecular Weight: Not specified for this item; refer to CoA/Spec Sheet.

  • Literature/context (general for synthetic peptides)

    • Physical state: Typically supplied as lyophilized solid or film; hygroscopicity can vary with composition.
    • Solubility: Sequence‑dependent. Many short peptides dissolve in water, aqueous buffers (e.g., PBS), dilute acids (0.1–1% acetic acid), or organic cosolvents (DMSO). Hydrophobic sequences may require initial dissolution in DMSO or isopropanol followed by dilution into aqueous buffer with gentle sonication.
    • pKa: Multiple ionizable groups (e.g., Lys/Arg/His side chains, terminal groups, Asp/Glu). Net charge and isoelectric point depend on sequence; verify with the specific sequence or CoA.
    • LogP: Not meaningful for polyionic peptides; amphipathic behavior is common and better described by hydropathy indices.
    • Stability: Peptides are generally stable when dry and protected from moisture, light, and oxidants. In solution, stability depends on pH, temperature, and sequence (Met, Cys, Trp prone to oxidation; Asp–Gly to hydrolysis at high pH).
    • Optical properties: Many peptides lack strong chromophores; UV at 214 nm (peptide bond) and 280 nm (Trp/Tyr) is commonly used for analytics.

  • Note: No item-specific BP/MP/density/refractive index values are provided. For any quantitative property, consult the CoA/Spec Sheet.

Quality and Grades

  • Item-specific

    • Grade: Moligand™ (as provided). No explicit purity percentage, counterions, sequence confirmation method, or residual solvent/metal limits are stated for this item. For definitive specifications, refer to the CoA/Spec Sheet.

  • Context (general)

    • Moligand™ is used to denote screening‑ready ligand materials in discovery libraries (small molecules or peptidic ligands). Such materials are typically suitable for biochemical/biophysical screening, assay development, and early SAR exploration. Exact acceptance criteria (e.g., identity confirmation by MS/HPLC, purity threshold, salt form) are lot‑specific.
    • Implications for use:
      • Analytical: Verify identity/purity in‑house if your application is highly purity‑sensitive (e.g., quantitative biophysics). Peptides are commonly characterized by LC‑MS and analytical RP‑HPLC.
      • Assay readiness: Libraries often emphasize solubility and reproducibility in standard solvents (water, buffer, DMSO). Nonetheless, pre‑screen solubility at intended assay concentrations.
    • Documentation: Always consult the CoA for batch‑specific sequence, salt form (e.g., TFA, acetate), residual solvents, water content, and recommended handling notes.
Reaction and Applications

  • Item-specific

    • Manufacturer application notes are not provided for this item.

  • Literature/context (typical uses of defined peptide fragments)

    • Biochemical probe: Defined OSTN fragments can be evaluated in receptor/ligand binding assays, pull‑downs, or biophysical platforms (SPR, BLI, MST) to characterize interactions with candidate binding partners.
    • Signaling studies: Exogenous peptide segments are often used to dissect domains responsible for receptor engagement, clearance receptor competition, or downstream signaling modulation in cell‑free or cell‑based assays.
    • Assay development: Serves as a positive/negative control peptide in ELISA‑like or fluorescence polarization displacement assays, depending on labeling.
    • Analytical standards: Useful as LC‑MS retention time/calibration standards if sequence and modifications are defined.

  • Practical tips (general)

    • Prepare concentrated stocks in water or DMSO depending on hydropathy; filter (0.22 µm) if assay permits.
    • Minimize freeze‑thaw by aliquoting; for high‑throughput screening, prepare plate‑ready DMSO stocks with humidity control.
    • Protect from oxidation if susceptible residues (Met, Cys, Trp) are present; include inert atmosphere or antioxidants only if compatible with downstream assays.

Note: All uses are for research purposes only.

Reaction Conditions

  • Item-specific

    • No reaction conditions are specified for this item.

  • Literature/context (handling and solution preparation for peptides)

    • Stock solutions: Prepare at 1–10 mM in water, buffer, or DMSO depending on solubility. Gentle warming (25–37°C) and brief sonication can assist dissolution. Avoid high temperatures and prolonged exposure to strong acids/bases.
    • Working concentrations: nM–µM for receptor/ligand assays and biophysics; optimize empirically.
    • Compatibility: Peptide integrity is generally maintained in neutral aqueous buffers. Avoid oxidants if Met/Cys/Trp residues are present; include reducing agents (e.g., 0.5–1 mM TCEP) only if compatible with the assay.
    • Filtration/sterility: If sterile solutions are required, filter through 0.22 µm low‑binding membranes. Some adsorption losses may occur; pre‑rinse filters or include carrier protein if assay allows.

Note: The above are general, literature‑based practices for peptide handling rather than specifications for this item.

Safety and Handling

  • GHS/SDS (item-specific)

    • Signal Word: Not specified for this item; refer to SDS.
    • H-Statements: Not specified for this item; refer to SDS.
    • GHS Classification and Pictograms: Not specified for this item; refer to SDS.

  • General laboratory precautions (peptide materials; literature/good practice)

    • Handle powders in a clean, dry area to minimize moisture uptake and aerosolization. Use appropriate PPE: lab coat, safety glasses, and nitrile gloves.
    • Avoid inhalation of dust; weigh in a fume hood or draft‑free enclosure if fine particulate is present.
    • Incompatibilities: Strong oxidizers may degrade sulfur‑containing or aromatic residues; strong bases/acids can catalyze backbone hydrolysis or deamidation depending on conditions.
    • Hygiene: Wash hands thoroughly after handling. Avoid contact with skin, eyes, and clothing.
    • First aid (general): If inhaled—move to fresh air; if on skin—wash with soap/water; if in eyes—rinse cautiously with water for several minutes; if swallowed—rinse mouth. Seek medical advice as needed. Defer to SDS for authoritative guidance.

  • Disposal

    • Dispose of unused material, solutions, and contaminated consumables according to institutional and local regulations for non‑hazardous organic laboratory chemicals, unless SDS indicates otherwise.
Solvent Selection

  • Item-specific

    • No solvent recommendations are specified for this item; consult the CoA/Spec Sheet.

  • Literature/context (peptide fragments)

    • Polarity class: Strongly polar, polyfunctional; net charge depends on sequence and pH.
    • Primary choices:
      • Aqueous: Water, PBS, HEPES, or ammonium bicarbonate buffers are common for neutral to basic peptides; 0.1–1% acetic acid or 10–20 mM HCl can aid dissolution of basic peptides.
      • Organic cosolvents: DMSO is a universal pre‑solvent for hydrophobic sequences; isopropanol or ethanol can assist before dilution into buffer. Avoid high DMSO in sensitive assays.
    • Practical workflow:
      • Start with water or buffer; if insoluble, add small aliquots of DMSO to form a clear concentrate, then back‑dilute into buffer with gentle vortexing/sonication.
      • For strongly basic peptides, acidify slightly; for acidic peptides, consider basic buffers (e.g., 10–50 mM ammonium bicarbonate, pH 8.0).
    • Comparison (general):
      • Water/buffer: Best for biological assays; limited for very hydrophobic sequences.
      • DMSO: Maximizes solubility; may interfere with some readouts above 1–2% v/v.
      • Acetonitrile: Useful for HPLC/mobile phases; less favored for long‑term storage solutions.
Storage and Reconstitution

  • Item-specific (from Product Data)

    • Storage Conditions (as supplied): Room temperature.
    • Shipped In: Not specified for this item; refer to CoA/Spec Sheet.
    • Reconstitution: Not specified for this item; refer to CoA/Spec Sheet.

  • General guidance (literature; verify compatibility with your application)

    • Upon receipt, keep container tightly closed in a dry environment. If long‑term storage is anticipated after opening, consider desiccation and inert headspace to limit moisture/oxidation.
    • For solution stocks, prepare single‑use aliquots to avoid repeated freeze–thaw. Store aliquots at temperatures appropriate for your workflow (commonly −20°C for peptides in aqueous buffer or DMSO), unless the CoA specifies otherwise.
    • Record solvent, concentration, pH, and date of preparation on each aliquot. Inspect for precipitation or discoloration before use.

Note: Always defer to the item’s CoA/SDS for definitive storage and handling instructions.

Structure and Identity

  • Item-specific (from Product Data)

    • SKU: rp174705
    • Product Name: OSTN (81-102)
    • CAS: rp174705 (catalog placeholder)
    • Grade/Purity: Moligand™
    • Storage Condition: Room temperature (as supplied)
    • InChIKey: 191466 (as provided)
    • Molecular Formula: Not specified for this item; refer to CoA/Spec Sheet.
    • Molecular Weight: Not specified for this item; refer to CoA/Spec Sheet.
    • SMILES: Not specified for this item; refer to CoA/Spec Sheet.

  • Literature/context (general)

    • OSTN denotes osteocrin, a secreted peptide/protein. “(81–102)” commonly indicates a C‑terminal peptide segment encompassing residues 81 through 102 of the full-length sequence (i.e., a 22‑mer), though exact sequence and any post‑translational modifications must be confirmed on the CoA.
    • Structural features expected for peptide fragments include a backbone of repeating amide (peptide) bonds, side chains bearing diverse functionalities (acidic, basic, polar, hydrophobic), and terminal amino and carboxyl groups unless capped. Peptides of this length are typically flexible in solution and may adopt local secondary structure motifs depending on solvent and concentration.

  • 2D description (general)

    • Linear polypeptidic chain with alternating carbonyl (C=O) and amide N–H along the backbone; pendant side chains vary by residue identity. N‑terminus may be free (–NH2/–NH3+) or modified; C‑terminus may be –COOH/–COO– or amidated—details are item-specific and should be verified on the CoA.
Synthetic Utility

  • Applicability to synthesis

    • As a defined peptide fragment, OSTN (81‑102) is not typically employed as a reagent or building block in classical small‑molecule synthesis. Therefore, its direct synthetic utility is limited.

  • Literature/context (peptide chemistry)

    • Peptides can serve as sequence‑defined scaffolds for SAR studies, conjugation to dyes/labels (e.g., via N‑terminal amine, Lys side chains, or click handles if present), or as antigens for raising antibodies. Such uses depend on the presence and accessibility of functional groups within the specific sequence.
    • If orthogonal handles are present (Azidohomoalanine, propargylglycine, etc.), CuAAC or SPAAC can be used for bioconjugation. Disulfide chemistry applies if cysteines are present.

  • Bottom line

    • For synthetic chemists, this material is best viewed as a bioactive probe or assay ligand rather than a general reagent. For chemical transformations or derivatizations, confirm sequence and protecting/terminal groups on the CoA.
Target Specificity

  • Item-specific

    • No target, receptor, or binding specificity data are provided for this product. Not specified for this item; refer to CoA/Spec Sheet.

  • Note

    • Any hypothesis about targets should be validated experimentally with the specific lot and sequence information.

Need help choosing the grade?

Our grade selection guide covers purity, stabilizer status, and application suitability for all variants in our catalog.

View Moligand™ grade guide →
Bulk & Custom Packaging Need larger quantities or custom specifications? Contact our team for a tailored quote.

View related series

chemerin receptor 2 Agonist (3)
We use cookies to ensure the website functions properly and, where permitted, to improve your experience. You can manage your preferences at any time in Settings. Learn more in our Cookie Policy.

Shall we send you a message when we have discounts available?

Remind me later

Thank you! Please check your email inbox to confirm.

Oops! Notifications are disabled.

Privacy Policy Terms of Use Cookie Policy Terms and Conditions of Sale Sales Policy
Products are supplied to verified businesses, institutions, and qualified professionals for research and development use only. Not for use in humans, animals, diagnosis, or therapy.
Copyright © 2023–present Aladdin Scientific Corp. All rights reserved.